The influence of carrier on 99mTc radiopharmaceuticals

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 3, 2002, Pages 224-232

  Ballinger, Jim R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Chelating agents; Chromatography high pressure liquid; Organotechnetium compounds; Radiopharmaceuticals; Technetium

Indexed keywords

CHELATING AGENT; GOLD; IODINE 123; LIGAND; LIPOCORTIN 5; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; RESIN; TECHNETIUM 99M; TECHNETIUM COMPLEX; THIOL; TECHNETIUM;

COST CONTROL; DRUG ACTIVITY; DRUG EFFICACY; DRUG LABELING; DRUG POTENCY; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG SYNTHESIS; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RECEPTOR BINDING; REVIEW; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; SOLVENT EXTRACTION; TOXICITY; CHEMICAL MODEL; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; ISOTOPE LABELING; METHODOLOGY;

CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; ISOTOPE LABELING; MODELS, CHEMICAL; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 0036707597     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. 4-: carrier free? J Nucl Med 1975;16:639-41.
2. Eckelman WC. Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur J Nucl Med 1995;22:249-63.
3. 99mTc-complexes. J Nucl Biol Med 1994;38:471.
4. Babich JW, Solomon H, Pike MC, Kroon D, Graham W, Abrams MJ et al. Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med 1993;34:1964-74.
5. 99mTc pyrophosphate by peroxides in pertechnetate used in preparation. J Nucl Med 1981;22:645-6.
6. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, Holmes RA et al. Technetium-99m d,1-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 1987;28:191-202.
7. Bayne VJ, Forster AM, Tyrrell DA. Use of sodium iodide to overcome the eluate age restriction for Ceretec™ reconstitution. Nucl Med Commun 1989;10:29-33.
8. Hnatowich DJ, Qu T, Chang F, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med 1998;39:56-64.
9. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol 2001;28:445-50.
10. George AJT, Jamar F, Tai M-S, Heelan BT, Adams GP, McCartney JE et al. Radiometal binding of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci U S A 1995;92:8359-62.
11. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996;23:1527-30.
12. 99m]-TRODAT-1. Nucl Med Biol 1999;26:461-6.
13. 1A receptor derived from desmethyl-MAY-100635 (DWAY). Eur J Nucl Med 2002;29:82-7.
14. Ohtsuki K, Akashi K, Aoka Y, Blankenberg FG, Kopiwoda S, Tait JF et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in vivo detection of apoptosis. Eur J Nucl Med 1999;26:1251-8.
15. 99mTc-annexin V. J Nucl Med 2001;42:382-7.
16. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PS et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;346:209-12.
17. 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med 2001;28:1373-8.
18. 99mTc. Bioconjugate Chem 2000;11:918-25.
19. 99mTc labeling of highly potent small peptides. Bioconjugate Chem 1997;8:621-36.
20. 99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjugate Chem 1995;6:635-8.
21. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. Bioconjugate Chem 1998;9:583-95.
22. 99mTc via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. Nucl Med Biol 2000;27:599-604.
23. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999;40:1913-7.
24. 99mTc. J Am Chem Soc 1999;121:6076-7.
25. 2+ (PXP=diphosphine ligand). Bioconjugate Chem 2001;12:1035-1042.
26. 1A receptor imaging agents. Nucl Med Biol 2002;29:217-26.
27. 99mTc labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 2001;28:657-66.
28. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694-9.
29. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 2001;42:1722-7.
30. 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. J Nucl Med 1999;40:244P.
31. 18F-6-fluoronicotine. Int J Appl Radiat Isot 1984;35:1125-8.
32. 99mTc-labeled chemotactic peptides for studies of inflammation in vivo. Bioconjugate Chem 1999;9:208-17.
33. Ballinger JR, Gulenchyn KY, Hassan MN. Technetium-99m spiperone dithiocarbamate: a potential radiopharmaceutical for dopamine receptor imaging with SPECT. Appl Radiat Isot 1989;40:547-9.
34. 99mTc-labeled chemotactic peptides: analogues with reduced neutropenia. Nucl Med Commun 1996;17:132-139.
35. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997;24:579-86.
36. 99mTc-labeled interleukin-8. J Nucl Med 2001;42:117-23.
37. 99mTc-interleukin-8 in rabbits. J Nucl Med 2001;42:917-23.
38. 99mTc complexes. In: Nicolini M, Bandoli G, Mazzi U, editors. Technetium and rhenium in chemistry and nuclear medicine. Padova, Italy: SG Editorali; 1995. p. 441-3.
39. Kao C-HK, Baidoo KE, Lever SZ. Validation and application of a solid phase chemistry method for preparation of high effective specific activity technetium-99m radiopharmaceuticals. Nucl Med Biol 1997;24:499-505.
40. Doyle AC. The adventure of the Empty House. The Strand Magazine; 1903. p. 26.
41. 99mTc radiopharmaceuticals using solid phase technology [abstract]. J Nucl Med 1995;36:27P.
42. Dunn-Dufault R, Pollak A, Thornback JR, Ballinger JR. Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology. Bioconjugate Chem 1999;10:832-7.
43. 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med 2001;42:154-61.
44. Dunn-Dufault R, Pollak A, Fitzgerald J, Thornback JR, Ballinger JR. Application of solid-phase no-carrier-added technetium-99m radiopharmaceutical preparation to the biotin-avidin system. Nucl Med Biol 2000;27:803-7.
45. Pollak A, Roe DG, Pollock CM, Lu LFL, Thornback JR. A convenient method of preparing high specific activity technetium complexes using thiol-containing chelators adsorbed on gold. J Am Chem Soc 1999;121:11593-4.
46. 99mTc radiopharmaceuticals generated using gold surfaces. J Nucl Med 2000;41:124P.
47. Johannsen B, Pietzsch H-J. Development of technetium-99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med 2002;29:263-75.
48. Breeman WAP, Kwekkeboom DJ, Kooij PPM, Bakker WH, Hofland LJ, Visser TJ et al.. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995;36:623-7.
49. Palestro CJ, Wieland FL, Seabold JE, Valdivia S, Tomas MB, Moyer BR, et al. Localizing infection with a technetium-99m-labeled peptide: initial results. Nucl Med Commun 2001;22:695-701.